Next Article in Journal
Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
Next Article in Special Issue
Breast Cancer Prognosis Using a Machine Learning Approach
Previous Article in Journal
Radiation Increases Functional KCa3.1 Expression and Invasiveness in Glioblastoma
Previous Article in Special Issue
Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Cancers 2019, 11(3), 280;

Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource

Department of Epidemiology and Health Statistics, XiangYa School of Public Health, Central South University, Changsha 410078, China
Department of Computational Physics, Institute of Modern Physics of Chinese Academy of Sciences, Lanzhou 730000, China
Department of Public Management, College of Economic Management, Changsha University, Changsha 410022, China
Author to whom correspondence should be addressed.
Received: 24 January 2019 / Revised: 16 February 2019 / Accepted: 22 February 2019 / Published: 26 February 2019
(This article belongs to the Special Issue Application of Bioinformatics in Cancers)
Full-Text   |   PDF [2634 KB, uploaded 26 February 2019]   |  
  |   Review Reports


To drive high-quality omics translational research using The Cancer Genome Atlas (TCGA) data, a TCGA Pan-Cancer Clinical Data Resource was proposed. However, there is an out-of-step issue between clinical outcomes and the omics data of TCGA for skin cutaneous melanoma (SKCM), due to the majority of metastatic samples. In clinical cases, the survival time started from the initial SKCM diagnosis, while the omics data were characterized at TCGA sampling. This study aimed to address this issue by proposing an observed survival interval (OBS), which was defined as the time interval from TCGA sampling to patient death or last follow-up. We compared the OBS with the usual recommended overall survival (OS) by associating them with both clinical data and microRNA sequencing data of TCGA-SKCM. We found that the OS of primary SKCM was significantly shorter than that of metastatic SKCM, while the opposite happened if OBS was compared. OS was associated with the pathological stage of both primary and metastatic SKCM, while OBS was associated with the pathological stage of primary SKCM but not that of metastatic SKCM. Five previously cross-validated survival-associated microRNAs were found to be associated with the OBS rather than OS in metastatic SKCM. Thus, the OBS was more appropriate for associating microRNA-omics data of TCGA-SKCM than OS, and it is a timely supplement to TCGA Pan-Cancer Clinical Data Resource. View Full-Text
Keywords: overall survival; observed survival interval; skin cutaneous melanoma; The Cancer Genome Atlas; omics overall survival; observed survival interval; skin cutaneous melanoma; The Cancer Genome Atlas; omics

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Xiong, J.; Bing, Z.; Guo, S. Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource. Cancers 2019, 11, 280.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top